Inhibition of glycogen synthase kinase-3 beta induces apoptosis and mitotic catastrophe by disrupting centrosome regulation in cancer cells

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Yoshino, Yuki ^a   Ishioka, Chikashi ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; GSK3B PROTEIN, HUMAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N-(4-METHOXYBENZYL)-N'-(5-NITRO-1,3-THIAZOL-2-YL)UREA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; THIAZOLE DERIVATIVE; UREA;

ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CENTROSOME; CHROMOSOMAL INSTABILITY; DOWN REGULATION; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; MITOSIS; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; SPINDLE APPARATUS; TUMOR CELL LINE;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CENTROSOME; CHROMOSOMAL INSTABILITY; DOWN-REGULATION; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; MITOSIS; NEOPLASMS; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SPINDLE APPARATUS; THIAZOLES; UREA;

EID: 84939832867     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13249     Document Type: Article

References (48)

1. Maurer, U., Preiss, F., Brauns-Schubert, P., Schlicher, L. & Charvet, C. GSK-3-at the crossroads of cell death and survival. J. Cell Sci. 127, 1369-78 (2014).
2. Takahashi-Yanaga, F. & Sasaguri, T. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J. Pharmacol. Sci. 109, 179-83 (2009).
3. Takahashi-Yanaga, F. Activator or inhibitor? GSK-3 as a new drug target. Biochem. Pharmacol. 86, 191-9 (2013).
4. Gao, X., Wang, J.-Y., Gao, L.-M., Yin, X.-F. & Liu, L. Identification and analysis of glycogen synthase kinase 3 beta1 interactome. Cell Biol. Int. 37, 768-79 (2013).
5. Zhou, B. P. et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6, 931-40 (2004).
6. Takahashi-Yanaga, F. & Sasaguri, T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell. Signal. 20, 581-9 (2008).
7. Zeng, J. et al. GSK3ß overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of nonsmall cell lung cancer cells. PLoS One 9, e91231 (2014).
8. Wang, Z. et al. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455, 1205-9 (2008).
9. Atkins, R. J., Stylli, S. S., Luwor, R. B., Kaye, A. H. & Hovens, C. M. Glycogen synthase kinase-3ß (GSK-3ß ) and its dysregulation in glioblastoma multiforme. J. Clin. Neurosci. 20, 1185-92 (2013).
10. Wakefield, J. G. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J. Cell Sci. 116, 637-646 (2002).
11. Izumi, N., Fumoto, K., Izumi, S. & Kikuchi, A. GSK-3beta regulates proper mitotic spindle formation in cooperation with a component of the gamma-tubulin ring complex, GCP5. J. Biol. Chem. 283, 12981-91 (2008).
12. Tighe, A., Ray-Sinha, A., Staples, O. D. & Taylor, S. S. GSK-3 inhibitors induce chromosome instability. BMC Cell Biol. 8, 34 (2007).
13. Ong Tone, S., Dayanandan, B., Fournier, A. E. & Mandato, C. A. GSK3 regulates mitotic chromosomal alignment through CRMP4. PLoS One 5, e14345 (2010).
14. Bilim, V. et al. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br. J. Cancer 101, 2005-14 (2009).
15. Eldar-Finkelman, H. & Martinez, A. GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front. Mol. Neurosci. 4, 32 (2011).
16. Pizarro, J. G. et al. Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons. Int. J. Dev. Neurosci. 26, 269-76 (2008).
17. Bhat, R. et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278, 45937-45 (2003).
18. Marchand, B., Tremblay, I., Cagnol, S. & Boucher, M.-J. Inhibition of glycogen synthase kinase-3 activity triggers an apoptotic response in pancreatic cancer cells through JNK-dependent mechanisms. Carcinogenesis 33, 529-37 (2012).
19. Zhou, W. et al. ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Cancer Lett. 316, 178-86 (2012).
20. Zhu, Q. et al. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate 71, 835-45 (2011).
21. Shakoori, A. et al. Inhibition of GSK-3 beta activity attenuates proliferation of human colon cancer cells in rodents. Cancer Sci. 98, 1388-93 (2007).
22. Holmes, T. et al. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth. Stem Cells 26, 1288-97 (2008).
23. Chen, H. et al. Inhibition of GSK-3beta decreases NF-kappaB-dependent gene expression and impairs the rat liver regeneration. J. Cell. Biochem. 102, 1281-9 (2007).
24. Hoeflich, K. P. et al. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406, 86-90 (2000).
25. Steinbrecher, K. A., Wilson, W., Cogswell, P. C. & Baldwin, A. S. Glycogen synthase kinase 3beta functions to specify genespecific, NF-kappaB-dependent transcription. Mol. Cell. Biol. 25, 8444-55 (2005).
26. Haefner, B. A model for NF-kappa B regulation by GSK-3 beta. Drug Discov. Today 8, 1062-3 (2003).
27. Dickey, A. et al. GSK-3ß inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line. J. Neurooncol. 104, 145-53 (2011).
28. Mirlashari, M. R., Randen, I. & Kjeldsen-Kragh, J. Glycogen synthase kinase-3 (GSK-3) inhibition induces apoptosis in leukemic cells through mitochondria-dependent pathway. Leuk. Res. 36, 499-508 (2012).
29. Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer. Cancer Res. 58, 1130-4 (1998).
30. Chen, W. et al. Structure-guided design of a highly selective glycogen synthase kinase-3beta inhibitor: A superior neuroprotective pyrazolone showing antimania effects. ChemMedChem 6, 1587-1592 (2011).
31. Teixido-Travesa, N., Roig, J. & Luders, J. The where, when and how of microtubule nucleation-one ring to rule them all. J. Cell Sci. 125, 4445-56 (2012).
32. Fukasawa, K. Oncogenes and tumour suppressors take on centrosomes. Nat. Rev. Cancer 7, 911-24 (2007).
33. Liu, Y. & Bodmer, W. F. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc. Natl. Acad. Sci. USA 103, 976-81 (2006).
34. Moore, P. S. et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. 439, 798-802 (2001).
35. O'Connor, P. M. et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285-300 (1997).
36. Morse, D. L., Gray, H., Payne, C. M. & Gillies, R. J. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol. Cancer Ther. 4, 1495-504 (2005).
37. Burgess, A., Rasouli, M. & Rogers, S. Stressing mitosis to death. Front. Oncol. 4, 140 (2014).
38. Fabbri, F. et al. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells. J. Cell. Physiol. 217, 494-501 (2008).
39. Ahmed, D. et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2, e71 (2013).
40. Kimura, M. et al. Mitotic catastrophe and cell death induced by depletion of centrosomal proteins. Cell Death Dis. 4, e603 (2013).
41. Loncarek, J., Hergert, P., Magidson, V. & Khodjakov, A. Control of daughter centriole formation by the pericentriolar material. Nat. Cell Biol. 10, 322-328 (2008).
42. Gritsko, T. et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 12, 11-9 (2006).
43. Bjorge, J. D. et al. Simultaneous siRNA targeting of Src and downstream signaling molecules inhibit tumor formation and metastasis of a human model breast cancer cell line. PLoS One 6, e19309 (2011).
44. Orr, B. & Compton, D. A. A double-edged sword: how oncogenes and tumor suppressor genes can contribute to chromosomal instability. Front. Oncol. 3, 164 (2013).
45. Naito, S. et al. Human renal cell carcinoma: establishment and characterization of two new cell lines. J. Urol. 128, 1117-21 (1982).
46. Naito, S. et al. Establishment of two human renal cell carcinoma cell lines with different chemosensitivity. Hum. Cell 9, 101-8 (1996).
47. Matsuzawa, A. et al. The BRCA1/BARD1-interacting protein OLA1 functions in centrosome regulation. Mol. Cell 53, 101-14 (2014).
48. Sekine, H. et al. S100A4, frequently overexpressed in various human cancers, accelerates cell motility in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 429, 214-9 (2012).